Previous 10 | Next 10 |
2024-02-02 15:00:00 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
2024-02-02 13:06:23 ET More on AbbVie AbbVie Q4 Earnings Preview: Few Clouds On Horizon Thanks To Masterful Management (Rating Upgrade) AbbVie Inc. (ABBV) JPMorgan 42nd Annual Healthcare Conference AbbVie: Still Expensive Despite The Great M&A Acumen AbbV...
2024-02-02 12:43:50 ET Summary Regeneron returned to topline growth in 2023 and this has led to the company's valuation rising to my expected EV/revenue range. The company is making significant investments in the obesity space, focusing on preserving lean mass and reducing fat mas...
2024-02-01 13:22:16 ET Short interest in healthcare stocks ticked higher from the end of 2023, with bets against healthcare provider and services ranking highest according to mid-January numbers. Read the full article on Seeking Alpha For further details see: Lilly, Zoetis, ...
2024-02-01 10:13:39 ET More on Bristol-Myers, Johnson & Johnson, etc. Pfizer Is Down 54% From Highs, Now Yields 6.1% Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value Pfizer: Reviewing Q4 Earnings, FY24 Guidance - Why I Disagree Wit...
2024-02-01 10:13:39 ET More on Bristol-Myers Squibb, Johnson & Johnson, etc. Pfizer Is Down 54% From Highs, Now Yields 6.1% Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value Pfizer: Reviewing Q4 Earnings, FY24 Guidance - Why I Disag...
2024-02-01 09:38:18 ET More on NeuroBo Pharmaceuticals Seeking Alpha’s Quant Rating on NeuroBo Pharmaceuticals Historical earnings data for NeuroBo Pharmaceuticals Financial information for NeuroBo Pharmaceuticals Read the full article on Seeking Alp...
2024-01-31 18:16:00 ET Eli Lilly (NYSE: LLY) stock eked out a gain on the stock market Wednesday, but the company doesn't necessarily have itself to thank for this. One of its rival pharmaceutical companies posted strong annual results fueled largely by a product category Lilly is e...
2024-01-31 13:25:01 ET Summary I forecast GLP-1 drugs to become the largest-selling pharmaceutical class, with US sales of $150 billion in 2030. GLP-1 agonists have shown favorable cardiovascular outcomes and beneficial effects on various organs, and in 2024 there will be data on ...
2024-01-31 12:32:57 ET More on Eli Lilly, Novo Nordisk, etc. Novo Nordisk A/S (NVO) Q4 2023 Earnings Call Transcript Biotech And Pharma Diversification Pays Off Novo Nordisk: Outlook For Weight Loss Drugs In 2024 Novo Nordisk stock hits all-time high as Wegov...
News, Short Squeeze, Breakout and More Instantly...
2024-07-29 15:13:21 ET Eli Lilly & Co (NYSE: LLY) has recently experienced a dramatic $123 billion decline in market value. This significant drop follows positive developments from competitors, notably Viking Therapeutics Inc and Roche Holding AG, who made announcements regarding th...
2024-07-29 09:20:00 ET While the market for anti-obesity medicines is characterized today by a fight between Novo Nordisk 's (NYSE: NVO) drug Wegovy and Eli Lilly 's (NYSE: LLY) drug Zepbound, that won't always be the case. Over the coming years, the competitive dynamics of ...
2024-07-29 07:30:00 ET When a major player announces good news in a lucrative market like weight loss drugs, it's often enough to drive shares of competitors down based on the assumption that they will have struggles ahead. That's just what happened after an announcement by Roche Hold...